Rinat Yerushalmi

9.4k total citations · 5 hit papers
119 papers, 6.7k citations indexed

About

Rinat Yerushalmi is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rinat Yerushalmi has authored 119 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Oncology, 52 papers in Cancer Research and 35 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rinat Yerushalmi's work include Breast Cancer Treatment Studies (43 papers), BRCA gene mutations in cancer (27 papers) and Advanced Breast Cancer Therapies (19 papers). Rinat Yerushalmi is often cited by papers focused on Breast Cancer Treatment Studies (43 papers), BRCA gene mutations in cancer (27 papers) and Advanced Breast Cancer Therapies (19 papers). Rinat Yerushalmi collaborates with scholars based in Israel, United States and Canada. Rinat Yerushalmi's co-authors include Karen A. Gelmon, Ryan Woods, Hagen F. Kennecke, Caroline Speers, Maggie C.U. Cheang, Malcolm Hayes, Torsten O. Nielsen, David Voduc, Peter M. Ravdin and Sara A. Hurvitz and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Rinat Yerushalmi

112 papers receiving 6.6k citations

Hit Papers

Metastatic Behavior of Br... 2010 2026 2015 2020 2010 2018 2010 2011 2020 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Metastatic Behavior of Breast Cancer Subtypes
    2010 1.6k citations Hagen F. Kennecke, Rinat Yerushalmi et al. profile →
  2. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
    2018 1.4k citations Jennifer K. Litton, Hope S. Rugo et al. New England Journal of Medicine profile →
  3. Ki67 in breast cancer: prognostic and predictive potential
    2010 899 citations Rinat Yerushalmi, Ryan Woods et al. The Lancet Oncology profile →
  4. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
    2011 850 citations Karen A. Gelmon, Marc Tischkowitz et al. The Lancet Oncology profile →
  5. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
    2020 252 citations Jennifer K. Litton, Sara A. Hurvitz et al. Annals of Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Rinat Yerushalmi 4.4k 2.3k 2.2k 1.8k 1.2k 119 6.7k
Joaquı́n Mateo 3.3k 0.8× 1.8k 0.8× 2.1k 1.0× 3.2k 1.8× 606 0.5× 148 6.1k
Rohit Bhargava 2.8k 0.6× 2.4k 1.0× 1.6k 0.7× 1.2k 0.7× 558 0.5× 171 5.5k
Michail Ignatiadis 3.8k 0.9× 3.8k 1.7× 2.3k 1.0× 1.5k 0.9× 525 0.5× 128 6.6k
Peter C.C. Fong 3.7k 0.8× 1.3k 0.5× 2.9k 1.3× 1.4k 0.8× 1.0k 0.9× 102 5.9k
Binghe Xu 6.1k 1.4× 3.0k 1.3× 3.2k 1.4× 2.8k 1.5× 1.2k 1.0× 387 9.1k
Pär‐Ola Bendahl 3.3k 0.7× 3.0k 1.3× 2.7k 1.2× 1.4k 0.8× 928 0.8× 181 6.7k
Hervé Bonnefoi 2.8k 0.6× 2.5k 1.1× 1.6k 0.7× 994 0.6× 588 0.5× 135 5.0k
Grazia Arpino 4.2k 0.9× 2.8k 1.2× 1.7k 0.8× 1.6k 0.9× 1.6k 1.4× 157 6.7k
Elena López‐Knowles 4.3k 1.0× 2.1k 0.9× 4.6k 2.1× 1.2k 0.7× 1.3k 1.1× 46 7.3k
Luc Dirix 2.8k 0.6× 1.8k 0.8× 3.8k 1.7× 1.1k 0.6× 865 0.7× 105 6.4k

Countries citing papers authored by Rinat Yerushalmi

Since Specialization
Citations

This map shows the geographic impact of Rinat Yerushalmi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rinat Yerushalmi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rinat Yerushalmi more than expected).

Fields of papers citing papers by Rinat Yerushalmi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rinat Yerushalmi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rinat Yerushalmi. The network helps show where Rinat Yerushalmi may publish in the future.

Co-authorship network of co-authors of Rinat Yerushalmi

This figure shows the co-authorship network connecting the top 25 collaborators of Rinat Yerushalmi. A scholar is included among the top collaborators of Rinat Yerushalmi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rinat Yerushalmi. Rinat Yerushalmi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alvarez‐Elizondo, Martha B., Annat Raiter, Rinat Yerushalmi, & Daphne Weihs. (2025). Chemotherapy-Induced Cell-Surface GRP78 Expression as a Prognostic Marker for Invasiveness of Metastatic Triple-Negative Breast Cancer. Annals of Biomedical Engineering. 53(4). 881–890. 1 indexed citations
2.
Yerushalmi, Rinat, Shani Paluch–Shimon, Lior Soussan‐Gutman, et al.. (2024). BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization. Breast Cancer Research and Treatment. 206(1). 67–76.
3.
Shachar, Shlomit Strulov, Michelle Leviov, Rinat Yerushalmi, et al.. (2023). Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry. npj Breast Cancer. 9(1). 79–79. 1 indexed citations
4.
Leviov, Michelle, Iryna Kuchuk, Shani Paluch–Shimon, et al.. (2023). Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study. npj Breast Cancer. 9(1). 49–49.
5.
6.
Leviov, Michelle, Iryna Kuchuk, Shani Paluch–Shimon, et al.. (2022). 149P Clinical outcomes in ER+ breast cancer patients with recurrence score 26-30-guided therapy: Real-world data. Annals of Oncology. 33. S607–S608. 1 indexed citations
7.
Yerushalmi, Rinat, Shani Paluch–Shimon, Frederick L. Baehner, et al.. (2022). 152P Molecular characterization by the 21-gene breast cancer (BC) Recurrence Score (RS) test of BRCA1/2 mutation carriers (mBRCA1/2) versus the general BC patient (pt) population. Annals of Oncology. 33. S609–S609. 1 indexed citations
8.
Moore, Assaf, Michal Sarfaty, Tzippy Shochat, et al.. (2021). Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer. The Breast. 60. 62–69. 101 indexed citations
9.
Goldstein, Daniel A., Tzippy Shochat, Assaf Moore, et al.. (2020). The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real‐world early‐stage breast cancer. Cancer Medicine. 9(13). 4603–4612. 4 indexed citations
10.
Amir, Eitan, Ariadna Tibau, Rinat Yerushalmi, et al.. (2020). National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study. Cancer Treatment Reviews. 91. 102113–102113. 5 indexed citations
11.
Litton, Jennifer K., HS Rugo, Johannes Ettl, et al.. (2018). Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation. Cancer Research. 78(4_Supplement). GS6–7. 40 indexed citations
12.
Litton, Jennifer K., Hope S. Rugo, Johannes Ettl, et al.. (2018). Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. New England Journal of Medicine. 379(8). 753–763. 1401 indexed citations breakdown →
13.
14.
Safra, Tamar, Bella Kaufman, Luna Kadouri, et al.. (2017). Everolimus Plus Letrozole for Treatment of Patients With HR+, HER2– Advanced Breast Cancer Progressing on Endocrine Therapy: An Open-label, Phase II Trial. Clinical Breast Cancer. 18(2). e197–e203. 11 indexed citations
15.
Goldvaser, Hadar, Shulamit Rizel, Daniel Hendler, et al.. (2016). The Association between Angiotensin Receptor Blocker Usage and Breast Cancer Characteristics. Oncology. 91(4). 217–223. 4 indexed citations
16.
Yust‐Katz, Shlomit, D. Liu, Yuan Yuan, et al.. (2013). Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis. Journal of Neuro-Oncology. 114(2). 229–235. 42 indexed citations
17.
Zer, Alona, Shulamit Rizel, Rony Braunstein, et al.. (2012). Tailoring Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Historical Prospective Study. Chemotherapy. 58(2). 95–101. 1 indexed citations
18.
Gelmon, Karen A., Marc Tischkowitz, Helen Mackay, et al.. (2011). Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. The Lancet Oncology. 12(9). 852–861. 850 indexed citations breakdown →
19.
Yerushalmi, Rinat, Scott Tyldesley, Ryan Woods, et al.. (2011). Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?. Annals of Oncology. 23(4). 876–881. 40 indexed citations
20.
Yerushalmi, Rinat, Mordechai R. Kramer, Shulamith Rizel, et al.. (2009). Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study. Annals of Oncology. 20(3). 437–440. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joaquı́n Mateo Breakdown of academic impact, for papers by Rohit Bhargava Breakdown of academic impact, for papers by Michail Ignatiadis Breakdown of academic impact, for papers by Peter C.C. Fong Breakdown of academic impact, for papers by Binghe Xu Breakdown of academic impact, for papers by Pär‐Ola Bendahl Breakdown of academic impact, for papers by Hervé Bonnefoi Breakdown of academic impact, for papers by Grazia Arpino Breakdown of academic impact, for papers by Elena López‐Knowles Breakdown of academic impact, for papers by Luc Dirix
Rankless by CCL
2026